Multiple law firms have filed a securities class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) after the company’s stock price collapsed 70.7 percent following the release of a U.S. Food and Drug Administration letter that questioned the reliability of its clinical trial data.
"The timeline raises important questions about when certain risks were known internally versus when they were disclosed to the investing public," said Joseph E. Levi of Levi & Korsinsky, one of the firms representing investors. "Shareholders who purchased ALDX stock in reliance on repeated assurances of consistent clinical results deserve answers."
The lawsuit alleges that between November 2023 and March 2026, Aldeyra made materially false and misleading statements regarding its dry-eye disease drug candidate, reproxalap. SEC filings described the drug as having "demonstrated broad-based, rapid-onset activity and consistent safety." However, on March 17, 2026, the company’s shares lost $2.99 apiece after the FDA’s Complete Response Letter revealed that clinical trial results were inconsistent and that positive findings were neither reliable nor meaningful.
The action contends that company leadership was aware of, or recklessly disregarded, these data shortcomings while continuing to make positive public statements. The lead plaintiff deadline for investors who purchased Aldeyra securities during the class period of November 3, 2023, to March 16, 2026, has been set for May 29, 2026.
According to the complaint, the FDA’s rejection was not based on a single, sudden failure but on a pattern of unreliable data. The agency noted a "lack of substantial evidence consisting of adequate and well-controlled investigations" and concluded that the "totality of evidence" from completed trials did not support the drug's effectiveness.
The lawsuit asserts that these were longstanding data issues that executives had a duty to disclose to investors. The complaint highlights that the same efficacy language was repeated across four consecutive annual and quarterly SEC filings without material qualification, while individual defendants were privy to the confidential clinical program information.
The sharp stock decline reflects the market's abrupt reassessment of reproxalap's approval prospects and potential commercial viability. Investors will now watch for Aldeyra's formal response to the lawsuit and any updates on its regulatory strategy ahead of the May 29 lead plaintiff deadline.
This article is for informational purposes only and does not constitute investment advice.
